611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Diverse Spectrum of Neurologic Syndromes Seen With ZikaExposure to Particulate Matter Linked to Metabolic AlterationsAir Purifiers May Help the Smog-Stressed Heart'Fat But Fit' a Myth?Statin Use Among Nursing Home Residents Varies SignificantlyZika Virus Tied to Neurological Woes in AdultsAn Expert's Guide to Preventing Food PoisoningHeart Risk Up if Hospitalized for Pneumonia or SepsisSinging May Be Good Medicine for Parkinson's PatientsCPAP Doesn't Alter Renal Function in Coexisting OSA, CVDWhen Stress Hormone Falters, Your Health May SufferKidney Disease May Boost Risk of Abnormal HeartbeatCertain Jobs Linked to Raised Risk of Rheumatoid ArthritisMidlife Vascular Risk Factors Tied to Increased Risk of DementiaHigher Risk of CVD Persists After Hospital Stay for Severe InfectionAntibiotic Doesn't Prevent Lung Complication After Stem Cell TransplantHealth Tip: One of Three Adults Gets ShinglesBlood Pressure Fluctuations Tied to Dementia Risk in StudyDecline in Kids' Ear Infections Linked to Pneumococcal VaccineFDA Approves Mavyret for Hepatitis CDoes Less Sleep Make You Less Healthy?Diabetes Drug Shows Promise Against Parkinson'sReview Suggests Benefits of Aerobic Exercise in FibromyalgiaNovel Procedure Improves Kidney Transplant SuccessABP 501, Adalimumab Biosimilar, Safe and Effective, for PsoriasisSimilar Defects ID'd for T2DM, Chronic Pancreatitis and DiabetesScientists Gain Insight Into AllergiesHealth Tip: Cooling a Heat RashKnow the Signs of ConcussionDo Your Pearly Whites Sometimes Cause You Pain?Rates of Inflammatory Bowel Disease Down in Rural AreasZika Probably Not Spread Through Saliva: StudyDrug for Kidney Disease Tied to Infection RiskGum Disease May Be Linked to Cancer Risk in Older WomenStent Surgery Could Benefit Select Glaucoma PatientsBlood Proteins Linked to Severity of Chronic Fatigue SyndromeDrowning Can Occur Hours After SwimmingClimate Change May Trigger 60,000 More Premature Deaths by 2030Health Tip: Worried About Lung Disease?Thyroid Cancer Tied to Regular Thyroxine Use in HypothyroidismGene Expression May Predict Response to Methotrexate in RAHealth Tip: Get the Facts About SalmonellaRush Hour Pollution May Be Worse Than ThoughtHow Chronic Fatigue Syndrome Wears Patients OutDonor Kidneys Rejected by Centers 7 Times on AverageMorphine Effects Similar to Placebo in Rheumatoid ArthritisHealth Tip: Learn Your Risk for AsthmaEczema Can Take a Toll on AdultsAOSSM: New Surgical Option for Irreparable Rotator Cuff TearsDrug Beats Steroids for Controlling Blood Vessel Inflammation in Study
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

ABP 501, Adalimumab Biosimilar, Safe and Effective, for Psoriasis


HealthDay News
Updated: Aug 2nd 2017

new article illustration

WEDNESDAY, Aug. 2, 2017 (HealthDay News) -- The biosimilar ABP 501 has similar clinical efficacy and safety to adalimumab for the treatment of moderate-to-severe plaque psoriasis, according to a study published online July 28 in the British Journal of Dermatology.

Kim Papp, M.D., Ph.D., from Clinical Research and Probity Medical Research in Waterloo, Canada, and colleagues randomized 308 patients (1:1) to receive ABP 501 or adalimumab (40 mg) every two weeks for 16 weeks. At week 16, patients with at least 50 percent improvement from baseline in psoriasis area-and-severity index score (PASI) were eligible to continue to Week 52 (152 patients), whereas adalimumab patients were re-randomized (1:1) to continue adalimumab (79 patients) or undergo a single transition to ABP 501 (77 patients).

The researchers found that PASI percent improvements were similar across groups for weeks 16, 32, and 50 (range, 85.8 to 88.2 percent), with no significant differences across groups in percentages of PASI 50, 75, 90, and 100 responders. Similarly, changes in percent body surface area affected were similar across groups and timepoints. There were no new safety issues reported, with adverse events similar between the groups.

"ABP 501 and adalimumab have similar clinical efficacy, safety, and immunogenicity profiles over 52 weeks, including after single transition, in this patient population," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Amgen, which manufactures ABP 501 and funded the study.

Abstract
Full Text (subscription or payment may be required)